134 related articles for article (PubMed ID: 25407396)
1. Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties.
Omar SI; Tuszynski J
Chem Biol Drug Des; 2015 Aug; 86(2):163-72. PubMed ID: 25407396
[TBL] [Abstract][Full Text] [Related]
2. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53.
Wassman CD; Baronio R; Demir Ö; Wallentine BD; Chen CK; Hall LV; Salehi F; Lin DW; Chung BP; Hatfield GW; Richard Chamberlin A; Luecke H; Lathrop RH; Kaiser P; Amaro RE
Nat Commun; 2013; 4():1407. PubMed ID: 23360998
[TBL] [Abstract][Full Text] [Related]
3. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.
Zhang Q; Bykov VJN; Wiman KG; Zawacka-Pankau J
Cell Death Dis; 2018 May; 9(5):439. PubMed ID: 29670092
[TBL] [Abstract][Full Text] [Related]
4. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
5. Restoration of p53 to limit tumor growth.
Wang W; El-Deiry WS
Curr Opin Oncol; 2008 Jan; 20(1):90-6. PubMed ID: 18043262
[TBL] [Abstract][Full Text] [Related]
6. Small molecules that reactivate mutant p53.
Bykov VJ; Selivanova G; Wiman KG
Eur J Cancer; 2003 Sep; 39(13):1828-34. PubMed ID: 12932659
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).
Degtjarik O; Golovenko D; Diskin-Posner Y; Abrahmsén L; Rozenberg H; Shakked Z
Nat Commun; 2021 Dec; 12(1):7057. PubMed ID: 34862374
[TBL] [Abstract][Full Text] [Related]
8. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ
Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067
[TBL] [Abstract][Full Text] [Related]
9. Restoration of conformation of mutant p53.
Green JA; Von Euler M; Abrahmsen LB
Ann Oncol; 2018 May; 29(5):1325-1328. PubMed ID: 29462239
[No Abstract] [Full Text] [Related]
10. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
11. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.
Bromley D; Bauer MR; Fersht AR; Daggett V
Protein Eng Des Sel; 2016 Sep; 29(9):377-90. PubMed ID: 27503952
[TBL] [Abstract][Full Text] [Related]
12. A new family of small molecules to probe the reactivation of mutant p53.
Myers MC; Wang J; Iera JA; Bang JK; Hara T; Saito S; Zambetti GP; Appella DH
J Am Chem Soc; 2005 May; 127(17):6152-3. PubMed ID: 15853303
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics.
Raghavan V; Agrahari M; Gowda DK
Comput Biol Chem; 2019 Jun; 80():398-408. PubMed ID: 31128451
[TBL] [Abstract][Full Text] [Related]
14. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
15. A molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53.
Shah HD; Saranath D; Murthy V
J Biomol Struct Dyn; 2022 Apr; 40(6):2407-2416. PubMed ID: 33111621
[TBL] [Abstract][Full Text] [Related]
16. Restoring p53-dependent tumor suppression.
Wang W; Rastinejad F; El-Deiry WS
Cancer Biol Ther; 2003; 2(4 Suppl 1):S55-63. PubMed ID: 14508081
[TBL] [Abstract][Full Text] [Related]
17. Dynamics and Molecular Mechanisms of p53 Transcriptional Activation.
Offutt TL; Ieong PU; Demir Ö; Amaro RE
Biochemistry; 2018 Nov; 57(46):6528-6537. PubMed ID: 30388364
[TBL] [Abstract][Full Text] [Related]
18. Targeting p53 by PTD-mediated transduction.
Wang W; El-Deiry WS
Trends Biotechnol; 2004 Sep; 22(9):431-4. PubMed ID: 15331219
[TBL] [Abstract][Full Text] [Related]
19. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Wiman KG
Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
